Blockchain Registration Transaction Record

Silo Pharma Collaborates with Frontage Laboratories to Conduct Safety Study of PTSD Treatment SPC-15

Silo Pharma partners with Frontage Laboratories to conduct a safety study of SPC-15, a treatment for PTSD and stress-related disorders. The collaboration aims to strengthen Silo's upcoming FDA submission, potentially expediting the approval process for the novel therapy.

This news matters as Silo Pharma's partnership for a safety study of SPC-15 showcases progress in developing treatments for psychiatric disorders. The study's outcomes could potentially expedite the FDA approval process for a novel therapy targeting PTSD, offering hope for patients suffering from stress-related conditions.